A cure‐rate model for Q‐learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients
Erica E. M. Moodie(McGill University), Elizabeth F. Krakow(Fred Hutch Cancer Center), Stephen R. Spellman(National Marrow Donor Program), Shomoita Alam(McGill University Health Centre), David A. Stephens(McGill University), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mei‐Jie Zhang(Medical College of Wisconsin), Mukta Arora(University of Minnesota Medical Center)
Cited by 9
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans
|Journal of Clinical Investigation|2010|516
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435